Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM)

Meletios A. Dimopoulos, MD, Robert Z. Orlowski, M.D., Ph.D, Thierry Facon, MD, Pieter Sonneveld, MD, Ph.D, Kenneth C. Anderson, MD, Meral Beksac, MD, Lotfi Benboubker, MD, Huw Roddie, MBChB, Ph.D, Anna Potamianou, MD, Catherine Couturier, PharmD, Huaibao Feng, Ph.D, Ozlem Ataman, MD, Ph.D, Helgi van de Velde, Paul G. Richardson, MD

Blood (2013) 122 (21): 3177.

https://doi.org/10.1182/blood.V122.21.3177.3177

Published: 2013

Journal Articles

A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM)

Sheeba K. Thomas, M.D., Tamara M Haygood, M.D., Muzaffar H. Qazilbash, MD, A. Georgina Melendez, M.D., Roxana Galvis, Kay B Delasalle, B.S., Lei Feng, M.S., Tiffany A. Richards, M.S., Felipe Samaniego, M.D., M.P.H, Luhua Wang, M.D., Jatin J. Shah, M.D., Robert Z. Orlowski, M.D., Ph.D., Donna M. Weber, M.D.

Blood (2013) 122 (21): 4396.

https://doi.org/10.1182/blood.V122.21.4396.4396

Published: 2013

Journal Articles

Obesity In Young Adulthood Is Associated With Early Onset Multiple Myeloma In African Americans

Blood (2013) 122 (21): 1872.

https://doi.org/10.1182/blood.V122.21.1872.1872

Published: 2013

Journal Articles

Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM)

Jatin J. Shah, M.D., Lei Feng, M.S., Sheeba K. Thomas, M.D., Donna M. Weber, M.D., Michael Wang, MD, Brandi Hilder, Raymond Alexanian, M.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 1982.

https://doi.org/10.1182/blood.V122.21.1982.1982

Published: 2013

Journal Articles

Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma

Jatin J. Shah, M.D., Veera Baladandayuthapani, PhD, Donna M. Weber, M.D., Sheeba K. Thomas, M.D., Raymond Alexanian, M.D., Michael Wang, MD, Muzaffar H. Qazilbash, MD, Richard E Champlin, MD, Nina Shah, MD, Qaiser Bashir, MD, Uday R Popat, MD, Yago Nieto, M.D., Ph.D., Sairah Ahmed, MD, Simrit Parmar, MD, Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 1983.

https://doi.org/10.1182/blood.V122.21.1983.1983

Published: 2013

Journal Articles

Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib

Arti Alagappan, Rupin A Shah, M.B.B.S, Sheeba K. Thomas, M.D., Donna M. Weber, M.D., Michael Wang, MD, Raymond Alexanian, M.D., Robert Z. Orlowski, M.D., Ph.D., Jatin J. Shah, M.D.

Blood (2013) 122 (21): 1994.

https://doi.org/10.1182/blood.V122.21.1994.1994

Published: 2013

Journal Articles

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

Blood (2013) 122 (21): 3187.

https://doi.org/10.1182/blood.V122.21.3187.3187

Published: 2013

Journal Articles

The Novel Human Double Minute (HDM)-2 Inhibitor DS-5272 Is Active Both Alone, and In Combination With Other Novel Agents, Against Multiple Myeloma

Dongmin Gu, M.D., Ph.D., Hua Wang, Ph.D., Zhiqiang Wang, Ph.D., Richard E. Davis, M.D., Shengli Cai, M.D., Ph.D., Takahiko Seki, Ph.D., Archie Tse, M.D., Ph.D., Robert Z. Orlowski, M.D., Ph.D

Blood (2013) 122 (21): 1927.

https://doi.org/10.1182/blood.V122.21.1927.1927

Published: 2013

Journal Articles

Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM)

Robert Z. Orlowski, M.D., Ph.D, Shadia Zaman, Ph.D., Sheeba K. Thomas, M.D., Raymond Alexanian, M.D., Jatin J. Shah, M.D., Donna M. Weber, M.D., Michael Wang, MD, Ashley N. Holloway, R.N., Veerabhadran Baladandayuthapani, Ph.D., Heather Yan Lin, Ph.D., Min Fu, Christine M. Stellrecht, Ph.D., Claudia Morales de Partovi, B.S., Varsha Gandhi, PhD

Blood (2013) 122 (21): 1953.

https://doi.org/10.1182/blood.V122.21.1953.1953

Published: 2013

Journal Articles

Autologous Stem Cell Transplantation Improves Survival For High Risk Cardiac Amyloidosis

Piyanuch Kongtim, MD, Muzaffar H. Qazilbash, MD, Jatin J. Shah, M.D., Robert Z. Orlowski, M.D., Ph.D., Amir Hamdi, MD, Nina Shah, MD, Qaiser Bashir, MD, Michael Wang, MD, Richard E Champlin, MD, Simrit Parmar, MD

Blood (2013) 122 (21): 3341.

https://doi.org/10.1182/blood.V122.21.3341.3341

Published: 2013

Journal Articles

High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma

Yago Nieto, MD, PhD, Nina Shah, MD, Uday R Popat, MD, Roy B Jones, PhD MD, Qaiser Bashir, MD, Rolland Bassett, MS, Benigno C. Valdez, PhD, Borje S Andersson, MD, PhD, Simrit Parmar, MD, Robert Z. Orlowski, M.D., Ph.D, Jatin J. Shah, M.D., Sheeba K. Thomas, M.D., Michael Wang, M.D., Richard E Champlin, MD, Muzaffar Qazilbash, M.D.

Blood (2013) 122 (21): 3346.

https://doi.org/10.1182/blood.V122.21.3346.3346

Published: 2013

Journal Articles

Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation

Maliha Nusrat, MD, Syed M. Kazmi, MD, Amanda Megan Cornelison, MS, PA-C, Partow Kebriaei, MD, Yago Nieto, MD, PhD, Betul Oran, MD, Robert Z. Orlowski, M.D., Ph.D., Simrit Parmar, MD, Uday R Popat, MD, Jatin J. Shah, M.D., Nina Shah, MD, Richard E Champlin, MD, Muzaffar H. Qazilbash, MD, Qaiser Bashir, MD

Blood (2013) 122 (21): 3358.

https://doi.org/10.1182/blood.V122.21.3358.3358

Published: 2013

Journal Articles

Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance

Anjan Thakurta, PhD, Anita K Gandhi, PhD, Michelle Waldman, MS, Chad C. Bjorklund, Ph.D., Suzanne Lentzsch, MD, PhD, Stephen A Schey, MD, Yolanda Calle, PhD, Rajani Chelliah, BSc, MSc, Robert Z. Orlowski, M.D., Ph.D, Anup Madan, PhD, Yuhong Ning, Derek Mendy, B.S., Antonia Lopez-Girona, PhD, Peter H Schafer, PhD, Herve Avet-Loiseau, MD, Rajesh Chopra, MD

Blood (2013) 122 (21): 3139.

https://doi.org/10.1182/blood.V122.21.3139.3139

Published: 2013

Journal Articles

Thalidomide, Lenalidomide and Pomalidomide Disrupt Epstein-Barr Virus (EBV) Latency: Clinical Implications

Richard Julian Jones, Ph.D., Shannon C. Kenney, MD, Christopher Dawson, PhD, Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 3499.

https://doi.org/10.1182/blood.V122.21.3499.3499

Published: 2013

Journal Articles

Expression Of Truncated Protein Tyrosine Phosphatase, Receptor Type, O (PTPROt) Influences Multiple Myeloma Sensitivity To Bortezomib Through Akt Signaling, and Is a Favorable Clinical Prognostic Factor

Hua Wang, Ph.D., Veerabhadran Baladandayuthapani, Ph.D., Zhiqiang Wang, Ph.D., Jiexin Zhang, Heather Yan Lin, Ph.D., Richard E. Davis, M.D., Lin Yang, Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 2520.

https://doi.org/10.1182/blood.V122.21.2520.2520

Published: 2013

Journal Articles

Plasmablastic Lymphoma: 28 Patient Single Institution Experience

Krina Patel, MD, Lei Feng, M.S., Yasuhiro Oki, MD, Muzaffar Qazilbash, M.D., Tariq Muzzafar, MBBS, Donna M. Weber, M.D., Nathan Fowler, MD, Uday R Popat, MD, Sheeba K. Thomas, M.D., Michelle A. Fanale, MD, Yago Nieto, MD, PhD, Nina Shah, MD, Qaiser Bashir, MD, Fredrick B. Hagemeister, MD, Robert Z. Orlowski, M.D., Ph.D., Jatin J. Shah, M.D.

Blood (2013) 122 (21): 4310.

https://doi.org/10.1182/blood.V122.21.4310.4310

Published: 2013

Journal Articles

CX-5461, a Novel RNA Polymerase I Inhibitor, Is Active Against Wild-Type and Mutant p53 Myeloma Models

Hans C. Lee, MD, Hua Wang, Ph.D., Bing-Zong Li, M.D., Ph.D., Zhiqiang Wang, Ph.D., Richard Julian Jones, Ph.D., Dongmin Gu, M.D., Ph.D., Sean O'Brien, Ph.D., Richard E. Davis, M.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 4438.

https://doi.org/10.1182/blood.V122.21.4438.4438

Published: 2013

Journal Articles

Activation Of Autophagy By Bone Marrow Adipocytes Protects Myeloma Cells From Chemotherapy-Induced Apoptosis

Jing Yang, PhD, Jingda Xu, PhD, Zhiqiang Liu, PhD, Jin He, Huan Liu, Pei Lin, MD, Robert Z. Orlowski, M.D., Ph.D, Larry W. Kwak, MD, PhD, Qing Yi, MD, PhD

Blood (2013) 122 (21): 1915.

https://doi.org/10.1182/blood.V122.21.1915.1915

Published: 2013

Journal Articles

Regulation Of DKK-1 Expression By p38 MAPK Signaling Via CREB Myeloma Cells

Jing Yang, PhD, Yuping Zhong, MD, Jin He, Zhiqiang Liu, PhD, Huan Liu, Pei Lin, MD, Robert Z. Orlowski, M.D., Ph.D., Larry W. Kwak, MD, PhD

Blood (2013) 122 (21): 1917.

https://doi.org/10.1182/blood.V122.21.1917.1917

Published: 2013

Journal Articles

Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia

Rupin A Shah, M.B.B.S, Satyajit Mohite, M.B.B.S., Veerabhadran Baladandayuthapani, Ph.D., Sheeba K. Thomas, M.D., Donna M. Weber, M.D., Michael Wang, MD, Raymond Alexanian, M.D., Muzaffar H Qazilbash, MD, Uday R Popat, MD, Richard E Champlin, MD, Nina Shah, MD, Qaiser Bashir, MD, Simrit Parmar, MD, Yago Nieto, MD, PhD, Sairah Ahmed, MD, Robert Z. Orlowski, M.D., Ph.D., Jatin J. Shah, M.D.

Blood (2013) 122 (21): 5356.

https://doi.org/10.1182/blood.V122.21.5356.5356

Published: 2013

NARROW

Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM)

A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM)

Obesity In Young Adulthood Is Associated With Early Onset Multiple Myeloma In African Americans

Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM)

Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma

Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

The Novel Human Double Minute (HDM)-2 Inhibitor DS-5272 Is Active Both Alone, and In Combination With Other Novel Agents, Against Multiple Myeloma

Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM)

Autologous Stem Cell Transplantation Improves Survival For High Risk Cardiac Amyloidosis

High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma

Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation

Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance

Thalidomide, Lenalidomide and Pomalidomide Disrupt Epstein-Barr Virus (EBV) Latency: Clinical Implications

Expression Of Truncated Protein Tyrosine Phosphatase, Receptor Type, O (PTPROt) Influences Multiple Myeloma Sensitivity To Bortezomib Through Akt Signaling, and Is a Favorable Clinical Prognostic Factor

Plasmablastic Lymphoma: 28 Patient Single Institution Experience

CX-5461, a Novel RNA Polymerase I Inhibitor, Is Active Against Wild-Type and Mutant p53 Myeloma Models

Activation Of Autophagy By Bone Marrow Adipocytes Protects Myeloma Cells From Chemotherapy-Induced Apoptosis

Regulation Of DKK-1 Expression By p38 MAPK Signaling Via CREB Myeloma Cells

Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only